TFF Pharmaceuticals Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
FORT WORTH, Texas, March 22, 2024 (GLOBE NEWSWIRE) — TFF Pharmaceuticals, Inc (Nasdaq:TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 147,500 shares of common stock at a purchase price of $8.00 per share. In a concurrent private placement, the Company also issued unregistered warrants to purchase up to 147,500 shares of common stock at an exercise price of $8.00 per share which are immediately exercisable for a period of five and one-half years following the date of issuance.